Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study

Cited by (266)

Items 101–200 of 266

1. Clinical characteristics and brain MRI findings in myeloproliferative neoplasms
   Koichiro Nagai, Takashi Shimoyama, Hiroki Yamaguchi, Yuki Sakamoto, Satoshi Suda, Satoshi Wakita, Yasuhiro Nishiyama, Koiti Inokuchi, Kazumi Kimura · 2020 · Journal of the Neurological Sciences
2. Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
   Alessandro Lucchesi, Roberta Napolitano, Maria Teresa Bochicchio, Giulio Giordano, Mariasanta Napolitano · 2021 · International Journal of Molecular Sciences
3. Thrombotic, Cardiovascular, and Microvascular Complications of Myeloproliferative Neoplasms and Clonal Hematopoiesis (CHIP): A Narrative Review
   Andrew I. Schafer, Douglas L. Mann · 2024 · Journal of Clinical Medicine
4. Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
   Francesca Palandri, Massimo Breccia, Elena Maria Elli, Roberto Latagliata, Giulia Benevolo, Erika Morsia, Mario Tiribelli, Francesco Cavazzini, Alessandra D’Addio, Alessia Tieghi et al. · 2025 · Leukemia
5. Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations
   Rie Aoyama, Yoshiaki Kubota, Shuhei Tara, Satoshi Wakita, Hiroki Yamaguchi, Wataru Shimizu, Hitoshi Takano · 2022 · International Heart Journal
6. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review
   Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eşkazan · 2023 · Expert Review of Hematology
7. Cytoreduction for ET and PV: who, what, when, and how?
   Douglas A. Tremblay · 2023 · Hematology
8. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
   Marko Lucijanić, Ivan Krečak, Ena Sorić, Anica Sabljić, Davor Galušić, Hrvoje Holik, Vlatka Periša, Martina Morić Perić, Ivan Zekanović, Josipa Budimir et al. · 2024 · Life
9. Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?
   Ofir Wolach, Adi Shacham Abulafia · 2021 · Hemato
10. Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms
    Orly Leiva, Andrew Jenkins, Rachel Pam Greenerger Rosovsky, Rebecca Karp Leaf, Katayoon Goodarzi, Gabriela Soriano Hobbs · 2023 · Hematology Reports
11. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia
    Nikolai Alexandrovich Podoltsev, Mengxin Zhu, Amer Methqal Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore, Xiaomei Ma · 2019 · Journal of the National Comprehensive Cancer Network
12. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention
    Marco Cattaneo, Lina Badimón, Giancarlo Agnelli, Andrew Tan Chan, Ángel Lanas, Bianca Rocca, Peter Malcolm Rothwell, Paola Patrignani, Ruth Elizabeth Langley, Gemma Vilahur et al. · 2020 · ecancermedicalscience
13. Arterial Thrombosis in Cancer Patients: An Update
    Massimo Franchini, Antonella Tufano, Aniello Casoria, Antonio Coppola · 2021 · Seminars in Thrombosis and Hemostasis
14. Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
    Olga Mulas, Brunella Mola, Alessandro Nanni Costa, Francesca Pittau, Daniela Mantovani, Samuele Dessì, Antonella Fronteddu, Giorgio La Nasa, Giovanni Caocci · 2023 · Annals of Hematology
15. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study
    Yoko Edahiro, Tomoki� Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito, Hideho Wada, Kensuke Usuki, Takayuki Tanaka et al. · 2022 · International Journal of Hematology
16. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
    Monia Marchetti, Jon Salmanton‐García, Shaimaa El‐Ashwah, Luisa Verga, Federico Itri, Zdeněk Ráčil, Julio Dávila, Sonia Martín‐Pérez, Jaap A. van Doesum, Francesco Passamonti et al. · 2023 · Therapeutic Advances in Hematology
17. Emerging agents and regimens for polycythemia vera and essential thrombocythemia
    R. Shallis, N. Podoltsev · 2021 · Biomarker Research
18. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions
    Hannah E. Goulart, John O Mascarenhas, Douglas A. Tremblay · 2022 · Annals of Hematology
19. Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia‐chromosome negative myeloproliferative neoplasms
    Vibe Skov, Mads Thomassen, Lasse Kjær, Morten Kranker Larsen, Trine Alma Knudsen, Christina Ellervik, Torben Arvid Kruse, Hans Carl Hasselbalch · 2023 · European Journal Of Haematology
20. From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?
    Jean‐Jacques Kiladjian, Tiziano Barbui · 2020 · Leukemia
21. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
    Tiziano Barbui, Antonello Gavazzi, Edoardo Sciatti, Maria Chiara Finazzi, Arianna Ghirardi, Greta Carioli, Alessandra Carobbio · 2023 · Current Hematologic Malignancy Reports
22. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights
    Erika Morsia, Elena Torre, Francesco Martini, Sonia Morè, Antonella Poloni, Attilio Olivieri, Serena Rupoli · 2024 · International Journal of Molecular Sciences
23. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms
    Mirjana Cvetković, Isidora Arsenović, Mihailo Smiljanić, Marta Sobas, Andrija D. Bogdanovic, Danijela Leković · 2024 · Annals of Hematology
24. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
    Andrew M. Peseski, Antoine N. Saliba, Sandra K. Althouse, Hamid Sayar · 2021 · Hematology/Oncology and Stem Cell Therapy
25. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth
    Jason R. Gotlib · 2022 · Blood
26. The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study
    Mohammadhossein Hajiebrahimi, Ci Song, David Hägg, Therése Andersson, Reginald Villacorta, Marie Linder · 2020 · Clinical Epidemiology
27. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study
    Aniket Bankar, Wing C. Chan, Ning Liu, Matthew C. Cheung, Shabbir M.H. Alibhai, Vikas K Gupta · 2023 · Blood Advances
28. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
    Andrew Tucker Kuykendall · 2023 · Annals of Hematology
29. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
    Joon Young Hur, Nayeon Choi, Jung Hye Choi, Jiyeong Kim, Young‐Woong Won · 2024 · Thrombosis Research
30. Applied genomics in MPN presentation
    Alison R. Moliterno, Hannah Kaizer · 2020 · Hematology
31. Chest Pain in the Cancer Patient
    Sara Moiz Tyebally, Aruni Ghose, Daniel H. Chen, Aderonke Abiodun, Arjun Kumar Ghosh · 2022 · European Cardiology Review
32. Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis
    Arumugam Manoharan, Rosalie Gemmell, Lauren Cavanaugh, Noor Shadood · 2022 · Clinical and Applied Thrombosis/Hemostasis
33. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
    Marc J. B. Dam, Rasmus Kristoffer Pedersen, Trine Alma Knudsen, Morten Andersen, Christina Ellervik, Morten Kranker Larsen, Lasse Kjær, Vibe Skov, Hans Carl Hasselbalch, Johnny T. Ottesen · 2022 · Cancer Medicine
34. Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms
    Kai Wille, Eva Deventer, Parvis Sadjadian, Tatjana M. Becker, Vera Kolatzki, Karlo Huenerbein, Raphael Meixner, Marina Jiménez‐Muñoz, Christiane Fuchs, Martin Grießhammer · 2023 · Hämostaseologie
35. Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
    Kasper Mønsted Pedersen, Yunus Çolak, Hans Carl Hasselbalch, Christina Ellervik, Børge Grønne Nordestgaard, Stig E. Bojesen · 2020 · EClinicalMedicine
36. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
    Tiziano Barbui, Valerio De Stefano · 2021 · Current Hematologic Malignancy Reports
37. Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study
    Sarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjærsgaard, Anna Stenling, Bianka Darvalics, Björn Paulsson, Christen Lykkegaard Andersen, Christian Fynbo Christiansen, Jesper Stentoft, Jørn Starklint et al. · 2022 · European Journal Of Haematology
38. Thromboses et thrombopathies dans les syndromes myéloprolifératifs
    Clélia Mornet, Hubert Galinat, Fanny Mingant, Jean‐Christophe Ianotto, Éric Lippert · 2020 · La Revue de Médecine Interne
39. Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
    Yoshitomo Hoshino, Katsunori Manaka, Junichiro Sato, Yui Asatsuma, Hirofumi Horikoshi, Maki Takeuchi, Nobuaki Ito, Megumi Fujita, Megumi Yasunaga, Kensuke Matsuda et al. · 2023 · BMC Endocrine Disorders
40. Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
    Ruth Stuckey, Cristina Bilbao, Adrián Segura-Díaz, María Teresa Gómez‐Casares · 2023 · International Journal of Molecular Sciences
41. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’
    Dipal Mehta, Samah Alimam, Donal P. McLornan, John Aaron Henry, Syeda Ahmed, Arjun Kumar Ghosh, Sara Moiz Tyebally, John Malcolm Walker, Riyaz S. Patel, Rodothea Amerikanou et al. · 2023 · Current Research in Translational Medicine
42. ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms
    Hassan K. Awada, Manasa Bhatta, Han Yu, Wenyan Ji, Surui Hou, Tara L. Cronin, Sheeba Ba Aqeel, Arya Mariam Roy, Muhammad Salman Faisal, Peter A. Kouides et al. · 2023 · Leukemia
43. Improving the investigative approach to polycythaemia vera: a critical assessment of current evidence and vision for the future
    Lukas Ronner, Sangeetha Venugopal, Erin L Moshier, John O Mascarenhas · 2021 · The Lancet Haematology
44. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
    Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine Alma Knudsen, Marko Lucijanić, Rajko Kušec · 2022 · Cancers
45. Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms
    Ayala Gat, Romi Kazoom, Inbal Shapira, Ela Shai, Batia Roth, Noa Buchman, Yosef Kalish, Ariela Arad, Eran Zimran · 2025 · Annals of Hematology
46. A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha
    Richard T. Silver, Hans Carl Hasselbalch · 2026 · Leukemia
47. Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data
    Suvir Singh, Jagdeep Singh, Arpan Mehta, Rintu Sharma, Kaveri Joshi, Kunal Jain, Davinder Paul, Gurleen Oberoi, Nandita Maini Jindal, Barjinderjit K. Dhillon et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
48. Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology
    Mehmet Baysal, Elif Aksoy, Kübra Hilal Bedir, Deniz Özmen, Püsem Patır, Ufuk Demirci, Samet Yaman, Zehra Narlı Özdemir, Vildan Gürsoy, Esra Yıldızhan et al. · 2024 · Journal of Thrombosis and Thrombolysis
49. WITHDRAWN: Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology
    Yuh Cai Chia, Marini Ramli, Peng Yeong Woon, Muhammad Farid Johan, Rosline Hassan, Md Asiful Islam · 2021 · Genes & Diseases · Retracted
50. Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia
    Erpeng Yang, Yan Lv, Ziqing Wang, Dehao Wang, Yumeng Li, Yan Sun, Yanyu Zhang, Jicong Niu, Zhuo Chen, Weiyi Liu et al. · 2022 · Frontiers in Medicine
51. The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
    Ji Yun Lee, Ju Hyun Lee, Woochan Park, Jeongmin Seo, Min-Su Kang, Eun Hee Jung, Sang‐A Kim, Koung Jin Suh, Ji‐Won Kim, Se Hyun Kim et al. · 2024 · Cancer Research and Treatment
52. Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative Neoplasms
    Alison R. Moliterno, Elizabeth V Ratchford · 2018 · Annals of Internal Medicine
53. JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients
    Tamar Shapira Cohen, Gabriel Chodick, David M. Steinberg, Ehud Grossman, Mordechai Shohat, Ophira Salomon · 2022 · Thrombosis and Haemostasis
54. Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group
    Marie Lindgren, Björn Andréasson, Jan Samuelsson, Helna Pettersson, Anneli Enblom‐Larsson, Anna Ravn Landtblom, Stefan Scheding, Carolina Bentham, Erik Ahlstrand · 2022 · European Journal Of Haematology
55. Patients with myeloproliferative neoplasms and COVID‐19 have increased rates of arterial thrombosis
    Orly Leiva, Umberto Campia, Julia Elizabeth Snyder, Briana M. Barns, Samantha M. Rizzo, Candrika D. Khairani, Andrew Mark Brunner, Hanny T. Al-Samkari, Rebecca Karp Leaf, Rachel Pam Greenerger Rosovsky et al. · 2022 · Research and Practice in Thrombosis and Haemostasis
56. Double trouble for cancer patients
    Alexander Thomas Cohen, Ingrid M. Bistervels · 2021 · European Heart Journal
57. Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register‐based matched cohort study
    Nurgul Batyrbekova, Malin L. Hultcrantz, Anna Ravn Landtblom, Robert Szulkin, Paul William Dickman, Therése Andersson, Elisavet Syriopoulou · 2025 · British Journal of Haematology
58. Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms
    Alexandre Guy, Olivier Mansier, Matisse Decilap, Alexandre Catherineau, Geoffrey Garcia, S. Colomer, Marie‐Lise Bats, Françoise Boyer, Jean‐Christophe Ianotto, Éric Lippert et al. · 2025 · Leukemia
59. Investigation and management of breakthrough ischemic stroke in anticoagulated patients with atrial fibrillation
    Ronda Lun, Umberto Pensato, Joseph R. Shaw, Carlo Andrea Pivato, Luciano Alberto Sposato, Thalia S. Field, Andrew M. Demchuk · 2026 · BMJ
60. The efficacy of erythrocyte apheresis for treatment of secondary erythrocytosis: An observational study
    Jie Ma, Qichao Yin, Fang Ye, Zhenzhen Ba, Hui Geng · 2024 · Medicine
61. Polycythemia vera as a rare cause of hypertension in a young man
    Maria V. Vetluzhskaya, Абрамова Антонина Аркадьевна, Оганесян Каринэ Арсеновна, Valery I. Podzolkov · 2021 · BMJ Case Reports
62. The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories
    Tiziano Barbui, Ayalew Tefferi, Alessandro Maria Vannucchi · 2025 · British Journal of Haematology
63. Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges
    Thita Chiasakul, Ross Ian Baker · 2025 · Journal of Clinical Medicine
64. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective
    Yiming Feng, Yue Zhang, Jialan Shi · 2022 · Platelets
65. Neutralize the neutrophils! Neutrophil β1/β2 integrin activation contributes to JAK2-V617F–driven thrombosis
    Stephen T. Oh · 2018 · Journal of Clinical Investigation
66. The roles of sex and genetics in the MPN
    Alison R. Moliterno, Evan M. Braunstein · 2022 · International review of cytology
67. Risk of thromboembolism according to statin treatment in patients with cancer: A nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim · 2024 · Thrombosis Research
68. Assessment of Systematic JAK2V617F Screening in 996 Patients With Venous Thromboembolism
    Norman Abbou, Julie Quessada, Antoine Tichadou, Robin Arcani, Régis T. Costello, Jean A. Gabert, Pierre‐Emmanuel Morange, Pierre Suchon, Geoffroy Venton · 2025 · American Journal of Hematology
69. Platelets display immunophenotypic alterations and dysregulated transcriptomic signature in Philadelphia-negative myeloproliferative neoplasms
    Vitor Leonardo Bassan, Poliana Carina Paolini, Lilian Maria Garcia Ramos, Fabiana Rossetto de Morais, Luciana Ambrósio, LFP Chaim, Patrícia Vianna Bonini Palma, Camila Bonaldo, Rafaela de Freitas Martins Felício, Lorena Lobo de Figueiredo‐Pontes et al. · 2025 · Thrombosis Research
70. Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival
    Anneli Enblom‐Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander · 2026 · European Journal Of Haematology
71. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery
    Mihaela Andreescu, Bogdan Andreescu · 2024 · Cureus
72. The evolving landscape of polycythemia vera therapies
    Juana Martinez, Shivani Handa, Alexander Skorodinsky, Marina Kremyanskaya · 2024 · Expert Opinion on Pharmacotherapy
73. Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults
    Aleksandra Ozygała, Joanna Rokosz-Mierzwa, Paulina Widz, Paulina Skowera, Mateusz Wiliński, Borys Styka, Monika Lejman · 2024 · Cancers
74. Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
    Valerio De Stefano, Francesco Passamonti, Francesca Palandri, Francesco Ramundo, Elena Rossi, Silvia Betti, Lorenzo Fagiolo, Paola Guglielmelli, Davide Pio Abagnale, Novella Pugliese et al. · 2025 · Annals of Hematology
75. Arterial thrombosis and second cancer in MPNs
    Murat O. Arcasoy · 2020 · Blood
76. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment
    Christopher Mazzeo, Moqing Quan, Helen Wong, Melissa A. Castiglione, Kenneth Kaushansky, Huichun Zhan · 2021 · Blood Cells Molecules and Diseases
77. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
    Barbara Mora, Francesco Passamonti · 2022 · Clinical Lymphoma Myeloma & Leukemia
78. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges
    Andrew Chua Tiu, Thita Chiasakul, Craig M. Kessler · 2023 · Seminars in Thrombosis and Hemostasis
79. Achievements and future outlook for JAK inhibitors in polycythaemia vera
    Ipek Cakmak, Claire N. Harrison · 2023 · Expert Opinion on Pharmacotherapy
80. Risk of myeloproliferative neoplasms among U.S. Veterans from Korean, Vietnam, and Persian Gulf War eras
    Andrew Chua Tiu, Zoe McKinnell, Shanshan Liu, Puneet Gill, Martha Antonio, Zoe Shancer, Nandan Srinivasa, Guoqing Diao, Ramesh Subrahmanyam, Craig M. Kessler et al. · 2024 · American Journal of Hematology
81. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms
    Donal P. McLornan, Claire N. Harrison · 2020 · British Journal of Haematology
82. MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too
    Anna Falanga · 2021 · Hematology
83. Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional study
    Emma-Louise Tarburn, Lisa Iversen, Charlotte Robertson, Charlene M. McShane, Andrew S. Duncombe, Mary‐Frances McMullin, Claire N. Harrison, Ruben A. Mesa, Lesley Ann Anderson · 2024 · BJGP Open
84. Clonal hematopoiesis and thromboembolic diseases: a review
    Jee Hyuk Byun, Jaekeun Jung, Janghee Woo · 2025 · Journal of Thrombosis and Haemostasis
85. Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases—Case-Based Narrative Review
    Anca Drăgan, Mădălina Găvănescu, Adrian Ştefan Drăgan, Alexandru Bardaş, Monica Dobrovie, Anca Doina Mateescu · 2025 · Biomedicines
86. Polycythemia vera
    Martin H. Ellis, Tiziano Barbui, Ayalew Tefferi · 2026 · Mayo Clinic Proceedings
87. Pulmonary Hypertension in Adults with Congenital Heart Disease
    Konstantinos Dimopoulos, Andrew Harry Constantine · 2023 · Springer eBooks
88. Extrahepatic portal hypertension in myeloproliferative diseases, features of diagnosis and therapeutic tactics
    P. A. Batrov, Elena Lukina, Karen Ismailovich Danishyan, Е. А. Киценко · 2024 · Endoscopic Surgery
89. Clinical and Neuroimaging Patterns of Ischemic Stroke in Ph-negative Myeloproliferative Neoplasms
    Marine Movsesovna Tanashyan, Кузнецова Полина Игоревна, Антон Алексеевич Раскуражев, Anait Levonovna Melikyan, Irina Nikolaevna Subortseva, А. А. Шабалина, Морозова Софья Николаевна · 2024 · Annals of Clinical and Experimental Neurology
90. The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
    Steffen Koschmieder · 2021 · Hemato
91. Neurologic complications of venous thromboembolism
    Michael J. Schneck · 2021 · Handbook of clinical neurology
92. Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021
    Jamie G Saunders, Natalia Curto‐García, Priya Sriskandarajah, Jennifer O’Sullivan, Claire Woodley, Susan Asirvatham, Marion Campbell-Drew, Jonathan Mathias, Tim Ellis, Nona Baker et al. · 2021 · HemaSphere
93. COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
    Kazuki Takasaki, Takazumi Tsunenari, Kazuma Mori, Satsuki Aochi · 2021 · BMJ Case Reports
94. Clinical characteristics and management of headache in patients with myeloproliferative neoplasms
    Takashi Shimoyama, Hiroki Yamaguchi, Kazumi Kimura, Fumiaki Suzuki, Toshiyuki Hayashi, Satoshi Wakita · 2022 · Frontiers in Neurology
95. Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms
    Sarah Kelliher, Sara Gamba, Luisa Weiß, Zhu Shen, Marina Marchetti, Francesca Schieppati, Caitríona Scaife, Stephen F. Madden, Kathleen Bennett, Anne Fortune et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
96. A JAK2 szomatikus génmutáció lehetséges betegségmódosító hatása a cardiovascularis kórképek kialakulásában
    Eszter Magyar, Anikó Újfalusi, Marianna Czenke, Gábor Méhes · 2024 · Orvosi Hetilap
97. What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?
    Helen O. Ajufo, Jennifer E. Vaughn · 2024 · Hematology
98. Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
    Tiziano Barbui, Valerio De Stefano, Elena Rossi, Arianna Ghirardi, Alessandra Carobbio, Giuseppe Gaetano Loscocco, Annalisa Condorelli, Paola Guglielmelli · 2025 · American Journal of Hematology
99. Janus kinase 2 mutation and venous thrombosis in Egyptian patients with Philadelphia negative chronic myeloproliferative neoplasms
    Mohamed A. Morad, Mervat Mattar, Heba Ibrahim, Yasser Elnahass, Heba Nader, Rasha Rawi · 2025 · The Egyptian Journal of Haematology
100. Patient Characteristics, Healthcare Contacts and Drug Use in Polycythaemia Vera in Denmark
     Karoline Mathilde Lundgaard, Dustin Andersen Patel, Mette Brabrand, Christen Lykkegaard Andersen, Anton Pottegård · 2025 · European Journal Of Haematology